Identification of KRBA1 as a Potential Prognostic Biomarker Associated with Immune Infiltration and m6A Modification in Hepatocellular Carcinoma

References

• Villanueva A, Longo DL. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–1462. doi:10.1056/NEJMra1713263
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.21262
   PubMed Web of Science ®Google Scholar
• Petrick JL, Kelly SP, Altekruse SF, McGlynn KA, Rosenberg PS. Future of hepatocellular carcinoma incidence in the United States forecast through 2030. J Clin Oncol. 2016;34(15):1787–1794. doi:10.1200/JCO.2015.64.7412
   PubMed Web of Science ®Google Scholar
• Pinero F, Dirchwolf M, Pessoa MG. Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response assessment. Cells-Basel. 2020;9(6):1370.
   PubMed Web of Science ®Google Scholar
• Clark T, Maximin S, Meier J, Pokharel S, Bhargava P. Hepatocellular carcinoma: review of epidemiology, screening, imaging diagnosis, response assessment, and treatment. Curr Probl Diagn Radiol. 2015;44(6):479–486. doi:10.1067/j.cpradiol.2015.04.004
   PubMed Web of Science ®Google Scholar
• Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology. 2002;122(6):1609–1619. doi:10.1053/gast.2002.33411
   PubMed Web of Science ®Google Scholar
• Bellefroid EJ, Poncelet DA, Lecocq PJ, Revelant O, Martial JA. The evolutionarily conserved Kruppel-associated box domain defines a subfamily of eukaryotic multifingered proteins. Proc Natl Acad Sci USA. 1991;88(9):3608–3612. doi:10.1073/pnas.88.9.3608
   PubMed Web of Science ®Google Scholar
• Edelstein LC, Collins T. The SCAN domain family of zinc finger transcription factors. Gene. 2005;359:1–17. doi:10.1016/j.gene.2005.06.022
   PubMed Web of Science ®Google Scholar
• Llorens C, Bernet GP, Ramasamy S, Feschotte C, Moya A. On the transposon origins of mammalian SCAND3 and KRBA2, two zinc-finger genes carrying an integrase/transposase domain. Mob Genet Elements. 2012;2(5):205–210. doi:10.4161/mge.22914
   PubMedGoogle Scholar
• Alexander J, Kalev O, Mehrabian S, et al. Familial early-onset dementia with complex neuropathologic phenotype and genomic background. Neurobiol Aging. 2016;42:199–204. doi:10.1016/j.neurobiolaging.2016.03.012
   PubMed Web of Science ®Google Scholar
• Zhu Y, Qiu P, Ji Y. TCGA-assembler: open-source software for retrieving and processing TCGA data. Nat Methods. 2014;11(6):599–600. doi:10.1038/nmeth.2956
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102. doi:10.1093/nar/gkx247
   PubMed Web of Science ®Google Scholar
• Xie P, Wang H, Xie J, et al. USP7 promotes proliferation of papillary thyroid carcinoma cells through TBX3-mediated p57(KIP2) repression. Mol Cell Endocrinol. 2020;518:111037. doi:10.1016/j.mce.2020.111037
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya S, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–658. doi:10.1016/j.neo.2017.05.002
   PubMed Web of Science ®Google Scholar
• Modhukur V, Iljasenko T, Metsalu T, Lokk K, Laisk-Podar T, Vilo J. MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. Epigenomics-UK. 2018;10(3):277–288. doi:10.2217/epi-2017-0118
   PubMed Web of Science ®Google Scholar
• Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956–D963. doi:10.1093/nar/gkx1090
   PubMed Web of Science ®Google Scholar
• Warde-Farley D, Donaldson SL, Comes O, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38(Web Server issue):W214–W220. doi:10.1093/nar/gkq537
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–15550. doi:10.1073/pnas.0506580102
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. doi:10.1158/0008-5472.CAN-17-0307
   PubMed Web of Science ®Google Scholar
• Zheng G, Ma Y, Zou Y, Yin A, Li W, Dong D. HCMDB: the human cancer metastasis database. Nucleic Acids Res. 2018;46(D1):D950–D955. doi:10.1093/nar/gkx1008
   PubMed Web of Science ®Google Scholar
• Ru B, Wong CN, Tong Y, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019;35(20):4200–4202. doi:10.1093/bioinformatics/btz210
   PubMed Web of Science ®Google Scholar
• Liu CJ, Hu FF, Xia MX, Han L, Zhang Q, Guo AY. GSCALite: a web server for gene set cancer analysis. Bioinformatics. 2018;34(21):3771–3772. doi:10.1093/bioinformatics/bty411
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. doi:10.1093/nar/gkv007
   PubMed Web of Science ®Google Scholar
• Keshet I, Schlesinger Y, Farkash S, et al. Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat Genet. 2006;38(2):149–153. doi:10.1038/ng1719
   PubMed Web of Science ®Google Scholar
• Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004;4(2):143–153. doi:10.1038/nrc1279
   PubMed Web of Science ®Google Scholar
• Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. doi:10.1038/nrdp.2016.18
   PubMed Web of Science ®Google Scholar
• Kulik LM, Chokechanachaisakul A. Evaluation and management of hepatocellular carcinoma. Clin Liver Dis. 2015;19(1):23–43. doi:10.1016/j.cld.2014.09.002
   PubMed Web of Science ®Google Scholar
• Pan Y, Chen H, Yu J. Biomarkers in hepatocellular carcinoma: current status and future perspectives. Biomedicines. 2020;8(12):576. doi:10.3390/biomedicines8120576
   PubMed Web of Science ®Google Scholar
• Fernandez-Barrena MG, Arechederra M, Colyn L, Berasain C, Avila MA. Epigenetics in hepatocellular carcinoma development and therapy: the tip of the iceberg. JHEP Rep. 2020;2(6):100167. doi:10.1016/j.jhepr.2020.100167
   PubMedGoogle Scholar
• Lee HS, Kim BH, Cho NY, et al. Prognostic implications of and relationship between CpG island hypermethylation and repetitive DNA hypomethylation in hepatocellular carcinoma. Clin Cancer Res. 2009;15(3):812–820. doi:10.1158/1078-0432.CCR-08-0266
   PubMed Web of Science ®Google Scholar
• Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol. 2003;163(4):1371–1378. doi:10.1016/S0002-9440(10)63495-5
   PubMed Web of Science ®Google Scholar
• Calvisi DF, Ladu S, Gorden A, et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest. 2007;117(9):2713–2722. doi:10.1172/JCI31457
   PubMed Web of Science ®Google Scholar
• Jin B, Wang W, Du G, et al. Identifying hub genes and dysregulated pathways in hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2015;19(4):592–601.
   PubMed Web of Science ®Google Scholar
• Tuo L, Xiang J, Pan X, et al. PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27(Kip1) axis. J Exp Clin Cancer Res. 2019;38(1):50. doi:10.1186/s13046-019-1029-y
   PubMed Web of Science ®Google Scholar
• Li B, Li A, You Z, Xu J, Zhu S. Epigenetic silencing of CDKN1A and CDKN2B by SNHG1 promotes the cell cycle, migration and epithelial-mesenchymal transition progression of hepatocellular carcinoma. Cell Death Dis. 2020;11(10):823. doi:10.1038/s41419-020-03031-6
   PubMed Web of Science ®Google Scholar
• Liang XH, Feng ZP, Liu FQ, et al. MAPRE1 promotes cell cycle progression of hepatocellular carcinoma cells by interacting with CDK2. Cell Biol Int. 2020;44(11):2326–2333. doi:10.1002/cbin.11442
   PubMed Web of Science ®Google Scholar
• Ding J, Li HY, Zhang L, Zhou Y, Wu J. Hedgehog signaling, a critical pathway governing the development and progression of hepatocellular carcinoma. Cells-Basel. 2021;10(1):123.
   PubMed Web of Science ®Google Scholar
• Oura K, Morishita A, Tani J, Masaki T. Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: a review. Int J Mol Sci. 2021;22(11):5801. doi:10.3390/ijms22115801
   PubMed Web of Science ®Google Scholar
• Shlomai A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol. 2014;26:78–88. doi:10.1016/j.semcancer.2014.01.004
   PubMed Web of Science ®Google Scholar
• Hato T, Goyal L, Greten TF, Duda DG, Zhu AX. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology. 2014;60(5):1776–1782. doi:10.1002/hep.27246
   PubMed Web of Science ®Google Scholar
• Fu Y, Liu S, Zeng S, Shen H. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38(1):396. doi:10.1186/s13046-019-1396-4
   PubMed Web of Science ®Google Scholar
• Xu F, Jin T, Zhu Y, Dai C. Immune checkpoint therapy in liver cancer. J Exp Clin Cancer Res. 2018;37(1):110. doi:10.1186/s13046-018-0777-4
   PubMed Web of Science ®Google Scholar
• Philips GK, Atkins M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol. 2015;27(1):39–46. doi:10.1093/intimm/dxu095
   PubMed Web of Science ®Google Scholar
• Huang H, Weng H, Chen J. m(6)A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer. Cancer Cell. 2020;37(3):270–288. doi:10.1016/j.ccell.2020.02.004
   PubMed Web of Science ®Google Scholar
• He L, Li H, Wu A, Peng Y, Shu G, Yin G. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18(1):176. doi:10.1186/s12943-019-1109-9
   PubMed Web of Science ®Google Scholar
• Chen M, Wong CM. The emerging roles of N6-methyladenosine (m6A) deregulation in liver carcinogenesis. Mol Cancer. 2020;19(1):44. doi:10.1186/s12943-020-01172-y
   PubMed Web of Science ®Google Scholar
• Wang P, Wang X, Zheng L, Zhuang C. Gene signatures and prognostic values of m6A regulators in hepatocellular carcinoma. Front Genet. 2020;11:540186. doi:10.3389/fgene.2020.540186
   PubMed Web of Science ®Google Scholar
• Shen S, Yan J, Zhang Y, Dong Z, Xing J, He Y. N6-methyladenosine (m6A)-mediated messenger RNA signatures and the tumor immune microenvironment can predict the prognosis of hepatocellular carcinoma. Ann Transl Med. 2021;9(1):59. doi:10.21037/atm-20-7396
   PubMed Web of Science ®Google Scholar
• Li Y, Qi D, Zhu B, Ye X. Analysis of m6A RNA methylation-related genes in liver hepatocellular carcinoma and their correlation with survival. Int J Mol Sci. 2021;22(3):1474.
   PubMed Web of Science ®Google Scholar
• Qin S, Mao Y, Chen X, Xiao J, Qin Y, Zhao L. The functional roles, cross-talk and clinical implications of m6A modification and circRNA in hepatocellular carcinoma. Int J Biol Sci. 2021;17(12):3059–3079. doi:10.7150/ijbs.62767
   PubMed Web of Science ®Google Scholar
• Wei Q. Bioinformatical identification of key genes regulated by IGF2BP2-mediated RNA N6-methyladenosine and prediction of prognosis in hepatocellular carcinoma. J Gastrointest Oncol. 2021;12(4):1773–1785. doi:10.21037/jgo-21-306
   PubMed Web of Science ®Google Scholar
• Chen M, Wei L, Law CT, et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology. 2018;67(6):2254–2270. doi:10.1002/hep.29683
   PubMed Web of Science ®Google Scholar
• Bian S, Ni W, Zhu M, et al. Identification and validation of the N6-Methyladenosine RNA methylation regulator YTHDF1 as a novel prognostic marker and potential target for hepatocellular carcinoma. Front Mol Biosci. 2020;7:604766. doi:10.3389/fmolb.2020.604766
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zeng F, Zeng M, et al. Identification and characterization of alcohol-related hepatocellular carcinoma prognostic subtypes based on an integrative N6-methyladenosine methylation model. Int J Biol Sci. 2021;17(13):3554–3572. doi:10.7150/ijbs.62168
   PubMed Web of Science ®Google Scholar
• Liu J, Sun G, Pan S, et al. The Cancer Genome Atlas (TCGA) based m(6)A methylation-related genes predict prognosis in hepatocellular carcinoma. Bioengineered. 2020;11(1):759–768. doi:10.1080/21655979.2020.1787764
   PubMed Web of Science ®Google Scholar
• Ikeda M, Morizane C, Ueno M, Okusaka T, Ishii H, Furuse J. Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Jpn J Clin Oncol. 2018;48(2):103–114. doi:10.1093/jjco/hyx180
   PubMed Web of Science ®Google Scholar